These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 30185381)

  • 1. Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer.
    Tseng JH; Cowan RA; Afonso AM; Zhou Q; Iasonos A; Ali N; Thompson E; Sonoda Y; O'Cearbhaill RE; Chi DS; Abu-Rustum NR; Long Roche K
    Gynecol Oncol; 2018 Nov; 151(2):287-293. PubMed ID: 30185381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.
    Suidan RS; Leitao MM; Zivanovic O; Gardner GJ; Long Roche KC; Sonoda Y; Levine DA; Jewell EL; Brown CL; Abu-Rustum NR; Charlson ME; Chi DS
    Gynecol Oncol; 2015 Aug; 138(2):246-51. PubMed ID: 26037900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
    Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR
    Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Gynecol Oncol; 2018 Aug; 150(2):233-238. PubMed ID: 29933927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
    Sioulas VD; Schiavone MB; Kadouri D; Zivanovic O; Roche KL; O'Cearbhaill R; Abu-Rustum NR; Levine DA; Sonoda Y; Gardner GJ; Leitao MM; Chi DS
    Gynecol Oncol; 2017 Apr; 145(1):15-20. PubMed ID: 28238354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of ultra-radical surgery in the management of patients with stage IIIC and IV epithelial ovarian, fallopian tube, and peritoneal cancer.
    Turnbull HL; Akrivos N; Wemyss-Holden S; Maiya B; Duncan TJ; Nieto JJ; Burbos N
    Arch Gynecol Obstet; 2017 Mar; 295(3):681-687. PubMed ID: 27995370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Success rate and safety of tumor debulking with diaphragmatic surgery for advanced epithelial ovarian cancer and peritoneal cancer.
    Saitou M; Iida Y; Komazaki H; Narui C; Matsuno K; Kawabata A; Ueda K; Tanabe H; Takakura S; Isonishi S; Sasaki H; Okamoto A
    Arch Gynecol Obstet; 2015 Mar; 291(3):641-6. PubMed ID: 25182215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of video laparoscopic surgical debulking of recurrent ovarian, fallopian tube, and primary peritoneal cancers.
    Nezhat FR; Denoble SM; Cho JE; Brown DN; Soto E; Chuang L; Gretz H; Saharia P
    JSLS; 2012; 16(4):511-8. PubMed ID: 23484556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers.
    Minaguchi T; Satoh T; Matsumoto K; Sakurai M; Ochi H; Onuki M; Oki A; Yoshikawa H
    Int J Clin Oncol; 2016 Jun; 21(3):573-9. PubMed ID: 26475355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer.
    Li S; Manning-Geist B; Gockley A; Ramos A; Sisodia RC; Del Carmen M; Growdon WB; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2020 Jul; 30(7):1052-1057. PubMed ID: 32487686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Laparoscopy to Assess Resectability in Stage IIIC Epithelial Ovarian, Tubal and Peritoneal Cancer Patients.
    Sánchez-Iglesias JL; Perez-Benavente A; Correa-Paris A; De la Torre Fernandez de Vega J; Carbonell Socias M; Gil-Moreno A
    Gynecol Obstet Invest; 2019; 84(3):259-267. PubMed ID: 30428466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience.
    Fagotti A; Vizzielli G; Fanfani F; Costantini B; Ferrandina G; Gallotta V; Gueli Alletti S; Tortorella L; Scambia G
    Gynecol Oncol; 2013 Nov; 131(2):341-6. PubMed ID: 23938372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?
    Worley MJ; Guseh SH; Rauh-Hain JA; Williams KA; Muto MG; Feltmate CM; Berkowitz RS; Horowitz NS
    Gynecol Oncol; 2013 Apr; 129(1):69-73. PubMed ID: 23375727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
    Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes.
    Nicklin JL; McGrath S; Tripcony L; Garrett A; Land R; Tang A; Perrin L; Chetty N; Jagasia N; Crandon AJ; Nascimento M; Walker G; Sanday K; Obermair A
    Aust N Z J Obstet Gynaecol; 2017 Dec; 57(6):651-658. PubMed ID: 28718942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C; Yao K; Li L; Yi T; Zhao X
    Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
    Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
    Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.